McKesson Lifted 2027 EPS to $45, but This $5B Buyback Is a Test of Confidence

Why the guidance raise matters more than one strong quarter

What changed this week was not McKesson's first-quarter report by itself. It was the company lifting its fiscal 2027 adjusted EPS guide to $44.20-$45.00 and pairing that with 13% to 15% growth instead of the prior 12% to 14%. That shifts the near-term debate: investors now have to value the stock against a higher earnings bar, not just last quarter's numbers.

Capital returns made the update more notable. McKesson returned $2.6 billion to shareholders in the quarter, and the board had previously added $5.0 billion to the repurchase authorization, bringing the total authorization to $7.7 billion as of April 2026. That does not prove the thesis, but it does suggest management feels confident enough in its cash generation to keep reducing the share count.

Yes, McKesson still trades at about 22.23x earnings, which is not cheap for a large distributor. The better question is whether that valuation still leaves room for upside if the company sustains the new EPS path, keeps building higher-value services, and continues to return cash.

What backed the raise: revenue, profit, and share reduction

The raised guide looks more credible because several parts of the results improved at once. McKesson posted $105.4 billion in revenue, up 8% while adjusted EPS reached $9.93, up 20%. Management also said operating profit grew 16%, with three segments delivering double-digit operating-profit growth. That gap between revenue growth and EPS growth suggests operating leverage, not just top-line momentum.

The mix shift is starting to show up in profit

The segment breakdown helps explain the leverage. North American Pharmaceutical operating profit increased 19%, Prescription Technology Solutions grew 13%, and oncology and multispecialty operating profit rose 41%. That does not mean McKesson is no longer a distributor. It does suggest the company is extracting more profit from a business mix that is gradually leaning into specialty and provider services.

The capital-structure angle matters too. McKesson said it plans about $5 billion of fiscal 2027 share repurchases, and it ended fiscal 2026 with $6.2 billion of operating cash flow and $5.4 billion of free cash flow. If that cash generation holds up, buybacks can become a second source of EPS growth on top of operating improvement.

Why management's operating depth matters

A guidance raise is easier to trust when the leadership team knows the business from the inside. Brian Tyler became McKesson's CEO in April 2019 after years of operating roles at the company, including president of North American Pharmaceutical Distribution and Services and a strategic role in mergers and acquisitions. He has been with McKesson since 1997.

The main watchpoint is consistency: a healthy mix tilt, broad-based segment profit growth, and durable cash conversion.

The debate: still early upside, or already a full-value stock?

The bullish case does not need to be sold. It needs to be stress-tested.

Why investors are split

Bulls can point to real momentum: McKesson has lifted its fiscal 2027 adjusted EPS guidance to $44.20 to $45.00, it still carries a 22.23 P/E ratio, and it returned $2.6 billion to shareholders in the quarter.

Bears can point to the business model's thin profit base. McKesson still has a net margin of 1.18% and negative return on equity of 345.35%. In other words, the company can produce strong per-share growth, but it does not have the deep profit margins of some premium market leaders. That makes entry price and follow-through more important.

What has to happen next

The practical test is straightforward. Investors should watch whether adjusted EPS keeps tracking the raised target, whether revenue holds up around or above the 12% fiscal 2026 revenue growth baseline, and whether segment profits continue to show the same mix advantage. Just as important, cash has to keep doing its job. McKesson previously reported $6.2 billion of operating cash flow and $5.4 billion of free cash flow, while management has signaled roughly $5 billion of fiscal 2027 share repurchases. If cash generation weakens, the buyback story gets less credible.

What would confirm or challenge the case

• Stay constructive if: adjusted EPS stays on the new path, revenue growth remains solid, segment profit growth stays broad-based, and shareholder returns remain firm.
• Get more selective if: management points to softer utilization, weaker specialty growth, slower provider-solutions adoption, or declining cash returns.

A buyback is easier to praise in theory than to fund in practice. McKesson still looks like a high-quality operator, but after this move, the premium multiple likely has to be earned over the next few quarters rather than assumed.